Library Open Repository

Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome

Downloads

Downloads per month over past year

Ding, C (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Current Opinion in Investigational Drugs, 7 (11). pp. 1020-1025. ISSN 1472-4472

[img]
Preview
PDF
vx-702.pdf | Download (221kB)
Available under University of Tasmania Standard License.

Abstract

Vertex Pharmaceuticals Inc, in collaboration with Kissei Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.

Item Type: Article
Journal or Publication Title: Current Opinion in Investigational Drugs
Page Range: pp. 1020-1025
ISSN: 1472-4472
Additional Information: restricted - published by Thompson
Date Deposited: 28 Mar 2008 00:47
Last Modified: 18 Nov 2014 03:32
URI: http://eprints.utas.edu.au/id/eprint/3610
Item Statistics: View statistics for this item

Repository Staff Only (login required)

Item Control Page Item Control Page